Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advancing Vision Research

Neither a doctor nor a teaching hospital

Research payments

$218,350

38 payments

Through program year 2025, Advancing Vision Research is reported as receiving $218,350 in research payments, across 38 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $36,058 10
2024 Research $13,157 3
2023 Research $76,577 9
2022 Research $63,663 11
2020 Research $4,000 1
2019 Research $24,896 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $130,790 19 payments
  2. Oyster Point Pharma, Inc. $49,214 13 payments
  3. Aerie Pharmaceuticals, Inc. $24,896 4 payments
  4. Novartis Pharmaceuticals Corporation $9,450 1 payment
  5. Mallinckrodt Hospital Products Inc. $4,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $117,167 16 payments
  2. A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $49,214 13 payments
  3. A Multicenter, Open-Label Study of Rhopressa (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma Or Ocular Hypertension in A Real-World Setting $24,896 4 payments
  4. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $12,059 1 payment
  5. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (PRK) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries $9,450 1 payment
  6. A Multicenter, Open-Label Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Severe Keratitis $4,000 1 payment
  7. AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $1,133 1 payment
  8. Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $431 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record